ClinConnect ClinConnect Logo
Search / Trial NCT06999967

Stanford-Lucidify EEG Delirium Study

Launched by STANFORD UNIVERSITY · May 23, 2025

Trial Information

Current as of July 23, 2025

Not yet recruiting

Keywords

Delirium Eeg Encephalopathy Cognitive Dysfunction Electroencephalography Delirium Monitoring

ClinConnect Summary

The Stanford-Lucidify EEG Delirium Study is a clinical trial aimed at improving how doctors detect delirium, a state of confusion that can affect people who are seriously ill. The study will use a special device called the CGX EEG system to monitor brain activity and a software program called Lucidify to help identify signs of delirium early on. By doing this, the researchers hope to better understand how delirium develops and how it can impact patients' movement, daily activities, and sleep quality. This is important because catching delirium early can lead to better care and outcomes for patients.

To participate in this study, individuals need to be 55 years or older and suspected of having delirium or at risk for it. They must be admitted to the Intensive Care Unit (ICU) or oncology wards and expected to stay in the hospital for more than a day. Participants will be closely monitored, and their brain activity and movements will be recorded to gather valuable information about their condition. It's important to note that this study is not yet recruiting participants, and certain individuals, such as those with specific neurological conditions or those who cannot communicate in English, will not be eligible to join.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age is 55 years or older
  • 2. Clinical suspicion of delirium or subject at risk for delirium
  • 3. Admitted to the Intensive Care Unit (ICU) or Oncology wards
  • 4. Expected hospital stay is greater than one (1) day
  • 5. Subject must be fluent in English
  • Exclusion Criteria:
  • 1. Age is younger than 55 years
  • 2. Subjects with a primary neurological or neurosurgical condition such as stroke, epilepsy, brain tumor, or witnessed seizures, Parkinson's disease, traumatic brain injury, or s/p craniectomy
  • 3. Active CNS substance abuse, intoxication, or withdrawal
  • 4. Unarousable or unresponsive subjects with RASS \<-3
  • 5. Subject is blind, deaf, or unable to speak or understand English

About Stanford University

Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.

Locations

Stanford, California, United States

Patients applied

0 patients applied

Trial Officials

José R Maldonado, M.D.

Principal Investigator

Stanford University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported